AstraZeneca to license lung cancer drug from China's Dizal Pharmaceutical
AI Summary
AstraZeneca has agreed to pay Dizal Pharmaceutical $600 million upfront for the global rights to a drug targeting lung cancer, as reported by the Chinese company in a filing. This acquisition could enhance AstraZeneca's oncology portfolio and strengthen its position in the competitive cancer treatment market.
AstraZeneca will pay Dizal Pharmaceutical $600 million upfront for global rights to one of its drugs for a type of lung cancer, the Chinese drugmaker said in a filing to the Shanghai stock exchange Tuesday.
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.
Original Article
Published on Hindu BusinessLine